Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Malignant neoplasm of urinary bladder
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Changes in the K-RAS gene in bladder cancers seem to be a rare event; this is in agreement with findings of other authors.
|
10958945 |
2000 |
Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mutation profiles of p53 and K-ras genes in pancreatic cancer resemble that in bladder cancer rather than that in lung cancer.
|
11561602 |
2002 |
Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A heterozygous deleted mutation was detected in K-RAS oncogene (exon 2) in agarose gel electrophoresis in one patient and point or substitution mutations are detected using single strand conformational polymorphism (SSCP) in other different patients with bladder cancer (4/14).
|
12092657 |
2001 |
Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To assess the frequency of specific point mutations in the K-ras gene in a group of Kashmiri patients with bladder cancer.
|
20845292 |
2010 |
Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The frequency of KRAS mutations in bladder cancer was estimated at 4.27 %.
|
23640097 |
2013 |
Malignant neoplasm of urinary bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Gene set enrichment analysis was conducted to study the relevant mechanisms.Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P < .0001), tumor grade (P = .001), T staging (P < .0001), N staging (P = .002), cancer specific survival (P < .0001), overall survival (P < .0001), and a trend of better M staging (P = .053) than those in COL5A2 high expression group.COL5A2 might affect the progression of bladder cancer through "Coagulation," "Hypoxia," "Apical junction," "Ultraviolet response," "Epithelial mesenchymal transition," "Angiogenesis," "KRAS (KRAS proto-oncogene, GTPase) signaling,"Complement,"IL2-STAT5-signaling," "Inflammatory response," "IL6-JAK-STAT3-signaling," "Myogenesis," "TNF α signaling," "Apoptosis," and "Hedgehog-signaling.
|
29517678 |
2018 |
Malignant neoplasm of urinary bladder
|
0.700 |
Biomarker
|
disease |
CTD_human |
Analysis of the relationship between pesticide exposure and mutation in the K-ras gene in human bladder cancer.
|
29644616 |
2018 |
Malignant neoplasm of urinary bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Since miR-143 silenced K-RAS and RAS effector-signaling molecules Erk and Akt, we performed the ectopic expression of miR-143 in human BC 253J-BV cells, and we examined the growth inhibition and the mechanism of it <i>in vitro</i> and in orthotopic model mice.
|
30911586 |
2019 |
Malignant neoplasm of urinary bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
Carcinogenic role of K-Ras-ERK1/2 signaling in bladder cancer via inhibition of H1.2 phosphorylation at T146.
|
31032946 |
2019 |
Malignant neoplasm of urinary bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer.
|
31066120 |
2019 |
Malignant neoplasm of urinary bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clinically relevant concentrations of the mutation prone KRAS fragment, which has been linked to colorectal, lung, and bladder cancer, were preconcentrated using the ITO-MIL strategy allowing for enrichment factors as high as 19.49 ± 1.44 from pure water and 4.02 ± 0.50 from 10-fold diluted plasma after a 1 min extraction.
|
31072469 |
2019 |